Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by ...

In an interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, explained how AI can help address clinical trial diversity and access challenges by reducing physician workload ...

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory ...

The partnership is centered around cutting cold chain costs and emissions with smart packaging and carbon-neutral same-day ...

In a recent interview with Applied Clinical Trials, Michel van Harten, MD, CEO of myTomorrows, discussed how AI is transforming clinical trials by reducing costs, accelerating timelines, and enhancing ...

In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also ...

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment ...

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization ...

In an exclusive sit-down with Pharma Commerce, Anne Cassity, senior vice president of government affairs for the National ...